The use of antibiotic bone cement has caught the attention of both supply chain organizations in hospitals as well as clinicians: from a supply chain perspective the additional cost (about three times the cost of regular bone cement) makes it a target for monitoring and negotiation; from a clinical perspective, anything that helps prevent joint infections would be welcome. Clinically there are questions of the efficacy of antibiotic bone cement, and whether its overuse will lead to superbugs.
What hasn’t been reported on are the difference in utilization and price of antibiotic bone cement from non-US sources. Since the FDA has allowed manufacturers to submit non-US data to support their applications for device clearances and approvals, it only makes sense to consider non-US sources for pricing differences.
Orthopedic Network News (ONN) was able to contact sources to compare prices of regular and antibiotic bone cement in England, France, Australia, and New Zealand. Although each of these countries do not perform as many joint replacements as is performed in the US, they all boast national pricing schedules and joint registries that allow tracking of outcomes. Annual joint replacement procedures in England were reported to be about 225,000, and about 118,000 in Australia, compared to about 1.7 million in the US.